source
- CSL shares plunge to nine-year low after cutting revenue forecast and announcing $5 billion impairmentCSL's shares fell to their lowest level since early 2017 after the company reduced its full‑year revenue guidance by roughly four percent. The guidance cut signals slower sales growth than previous…
- Rezdiffra Beats Wall Street Forecasts as MASH Market ExpandsRezdiffra, a drug candidate targeting metabolic dysfunction‑associated steatohepatitis (MASH), is outperforming analysts' expectations according to recent commentary. The optimism comes as the mar…